[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-334573-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-334573-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","immune-escape-and-metastasis-mechanisms-in-melanoma-breaking-down-the-dichotomy","Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy","","Melanoma remains among the most lethal skin cancers as immune checkpoint inhibitors still fail in many advanced cases, leading to primary and secondary resistance, ongoing recurrence, and limited long-term survival. Tumor cells evade immune control and metastasize through overlapping programs rather than two independent processes. Evidence reviewed here links immune escape and metastasis by “dual drivers,” including EMT-like dedifferentiation, neural crest stem cell maintenance gene programs, and hypoxia or acidosis, with differences and parallels to early dissemination. Targeting shared mechanisms may improve prevention of recurrence from dormant dissemination and enhance immunotherapy outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/immune-escape-and-metastasis-mechanisms-in-melanoma-breaking-down-the-dichotomy/334573/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/immune-escape-and-metastasis-mechanisms-in-melanoma-breaking-down-the-dichotomy/334573.png","ImageObject",300,407,{"name":42,"@type":43},"Anda","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-06","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What clinical problem does the review focus on in melanoma?","Question",{"text":63,"@type":64},"The review focuses on how metastatic spread, recurrence, and immune checkpoint inhibitor resistance limit effective treatment in advanced melanoma.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why does the review argue that immune escape and metastasis are linked rather than separate?",{"text":68,"@type":64},"Accumulating evidence indicates that the same melanoma progression programs simultaneously create immunosuppressive conditions and promote metastatic potential.",{"name":70,"@type":61,"acceptedAnswer":71},"Which mechanisms are highlighted as potential “dual drivers” for immune escape and metastasis?",{"text":72,"@type":64},"Key mechanisms include EMT-like dedifferentiation, neural crest stem cell maintenance gene programs, and hypoxia/acidosis that together support both immune evasion and metastasis.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},334573,1790197087,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":118,"language":139,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":12,"update_tm":143,"read_time":104,"preview_page_count":4},962075006959,"https://ap-avatar.wpscdn.com/avatar/e0002397efbe92a78e?_k=1776741047341049297","TYPE Review  \nPUBLISHED 14 February 2024  \nDOI 10.3389/fimmu.2024.1336023  \nOPEN ACCESS  \nEDITED BY  \nLaura Ridolﬁ,  \nScientiﬁc Institute of Romagna for the Study and Treatment of Tumors (IRCCS), Italy  \nREVIEWED BY  \nGeorg Wondrak,  \nUniversity of Arizona, United States Brian Koss,  \nUniversity of Arkansas for Medical Sciences, United States  \n*CORRESPONDENCE Nihal Ahmad  \n [nahmad@dermatology.wisc.edu](nahmad@dermatology.wisc.edu)  \n†These authors have contributed equally to this work  \nRECEIVED 09 November 2023  \nACCEPTED 24 January 2024  \nPUBLISHED 14 February 2024  \nCITATION  \nShirley CA, Chhabra G, Amiri D, Chang H and Ahmad N (2024) Immune escape and metastasis mechanisms in melanoma:  \nbreaking down the dichotomy.  \nFront. Immunol. 15:1336023 .  \ndoi: 10.3389/fimmu.2024.1336023  \nCOPYRIGHT  \n© 2024 Shirley, Chhabra, Amiri, Chang and Ahmad. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nImmune escape and metastasis mechanisms in melanoma: breaking down the dichotomy  \nCarl A. Shirley 1†, Gagan Chhabra 1†, Deeba Amiri 1, Hao Chang 1,2 and Nihal Ahmad 1,2*  \n1 Department of Dermatology, University of Wisconsin, Madison, WI, United States, 2William S. Middleton Memorial Veterans Hospital, Madison, WI, United States  \nMelanoma is one of the most lethal neoplasms of the skin. Despite the revolutionary introduction of immune checkpoint inhibitors, metastatic spread, and recurrence remain critical problems in resistant cases. Melanoma employs a multitude of mechanisms to subvert the immune system and successfully metastasize to distant organs. Concerningly, recent research also shows that tumor cells can disseminate early during melanoma progression and enter dormant states, eventually leading to metastases at a future time. Immune escape and metastasis have previously been viewed as separate phenomena; however, accumulating evidence is breaking down this dichotomy. Recent research into the progressive mechanisms of melanoma provides evidence that dedifferentiation similar to classical epithelial to mesenchymal transition (EMT), genes involved in neural crest stem cell maintenance, and hypoxia/ acidosis, are important factors simultaneously involved in immune escape and metastasis. The likeness between EMT and early dissemination, and differences, also become apparent in these contexts. Detailed knowledge of the mechanisms behind “dual drivers” simultaneously promoting metastatically inclined and immunosuppressive environments can yield novel strategies effective in disabling multiple facets of melanoma progression . Furthermore, understanding progression through these drivers may provide insight towards novel treatments capable of preventing recurrence arising from dormant dissemination or improving immunotherapy outcomes.  \nKEYWORDS  \nimmune escape, metastasis, EMT, hypoxia, acidosis, neural crest stem cell genes, dormancy, early dissemination  \n1 Introduction  \nMelanoma is a highly aggressive malignancy arising from melanocytes. Despite recent advances in melanoma research, the incidence of metastatic melanoma has only grown in the past decade (1–3) . Treatments often fail to effectively overcome the adaptive mechanisms driving melanoma, especially in metastatic instances (4–11) . Current  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nimmunotherapies for advanced stage melanomas involve antagonization of cytotoxic T-lymphocyte-associated protein-4 (CTLA-4, ipilimumab) and programmed cell death protein-1 (PD-1, nivolumab and pembrolizumab), but in 45-70% of cases these therapies encounter primary resistance (","cbCaitAWMjk80BrY","https://ap.wps.com/l/cbCaitAWMjk80BrY","pdf",12031009,"English","# Introduction\n## Immune checkpoint resistance and unmet clinical needs\n## Metastasis as a lethal driver\n## Rethinking linear progression and early dissemination\n## Linking immune escape with metastasis through dual drivers","[{\"question\":\"What clinical problem does the review focus on in melanoma?\",\"answer\":\"The review focuses on how metastatic spread, recurrence, and immune checkpoint inhibitor resistance limit effective treatment in advanced melanoma.\"},{\"question\":\"Why does the review argue that immune escape and metastasis are linked rather than separate?\",\"answer\":\"Accumulating evidence indicates that the same melanoma progression programs simultaneously create immunosuppressive conditions and promote metastatic potential.\"},{\"question\":\"Which mechanisms are highlighted as potential “dual drivers” for immune escape and metastasis?\",\"answer\":\"Key mechanisms include EMT-like dedifferentiation, neural crest stem cell maintenance gene programs, and hypoxia/acidosis that together support both immune evasion and metastasis.\"}]","Immune escape and metastasis mechanisms in melanoma: breaking down the dichotomy | PDF",1790007278]